Novel Alzheimer's therapy shows low risk of severe side effects
10 Articles
10 Articles
OSU looking for those with early Alzheimer's to participate in study
COLUMBUS, Ohio (WCMH) -- Ohio State University is in a recruiting state, but it has nothing to do with football. OSU is looking for people who are in the early stages of Alzheimer's to take part in a nationwide drug trial for a synthetic version of Vitamin B1. The drug is Benfotiamine, and lead researcher, Dr. Douglas Scharre, said it is critical for brain processing. "People who are deficient in Vitamin B1 can have significant problems with the…
Novel Alzheimer's therapy shows low risk of severe side effects
The Food and Drug Administration's approval in 2023 of lecanemab - a novel Alzheimer's therapy shown in clinical trials to modestly slow disease progression - was met with enthusiasm by many in the field as it represented the first medication of its kind able to influence the disease.
Alzheimer’s: The first medicine to stop the disease shows encouraging results
A new study by researchers at the University of Washington School of Medicine in St. Louis offers encouraging data on the safety of lecanemab, the first approved treatment to slow the progression of Alzheimer’s. According to research published in JAMA Neurology, the serious adverse effects associated with the drug are rare and, for the most part, manageable in real clinical settings.
Side Effects Update: Lecanemab To Slow Alzheimer's
In 2023, the U.S. Food and Drug Administration an Alzheimer’s therapy shown in clinical trials to modestly slow disease progression but side effects, brain swelling and bleeding, occurred in some.Though clinical trials have taken twice as long and cost twice as much due to government regulations, they can't cover everything and a successful doesn't mean broader demographics won't show different effects. Lawyers are gleeful at the opportunity to…
Coverage Details
Bias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage